CDA | Evidence Driven
CDA | Evidence Driven

Insulin glargine

Details

Files
Generic Name:
Insulin glargine
Project Status:
Complete
Therapeutic Area:
Diabetes mellitus, type 1; diabetes mellitus, type 2
Manufacturer:
Eli Lilly Canada Inc.
Call for patient/clinician input open:
Brand Name:
Basaglar
Project Line:
Reimbursement Review
Project Number:
SE0451-000
Call for patient/clinician input closed:
NOC Status at Filing:
Post NOC
Submission Type:
Initial
Indications:
Diabetes mellitus, Type 1 & 2
Recommendation Type:
List with clinical criteria and/or conditions
Final Recommendation:

Files

Submission Status Report View PDF
Recommendation and Reasons View PDF
Patient Group Input Submissions View PDF
Subsequent Entry Biologic Review Report View PDF
Last Updated : September 4, 2015